5 minute read
May 13, 2022

JDQ443: A Quickly-Advancing Oral KRAS(G12C) Inhibitor from Novartis

JDQ443

oral KRASG12C inhibitor ph. III candidate for NSCLC from de novo SBDD in SWII pocket Cancer Discov. Novartis, Basel, CH

twitterlinkedinprintemail